rsv lid/δm2-2/1030s
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2020 (NCT04520659)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04520659 | Phase 1 | Sep 1, 2020 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), Sanofi-Aventis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2020 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1